Axa S.A. Reduces Position in Haemonetics Co. (NYSE:HAE)

Axa S.A. decreased its position in Haemonetics Co. (NYSE:HAE - Free Report) by 11.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,400 shares of the medical instruments supplier's stock after selling 6,730 shares during the period. Axa S.A. owned approximately 0.10% of Haemonetics worth $4,013,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nordea Investment Management AB raised its stake in shares of Haemonetics by 5.5% in the fourth quarter. Nordea Investment Management AB now owns 104,175 shares of the medical instruments supplier's stock worth $8,152,000 after purchasing an additional 5,385 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in Haemonetics during the 4th quarter worth approximately $402,000. KBC Group NV lifted its stake in Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after acquiring an additional 712 shares during the period. Pacer Advisors Inc. boosted its holdings in shares of Haemonetics by 36.1% in the 4th quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock valued at $789,000 after acquiring an additional 2,680 shares during the last quarter. Finally, Boston Trust Walden Corp increased its stake in shares of Haemonetics by 13.1% in the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after acquiring an additional 106,114 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Trading Up 1.0 %

Shares of HAE stock opened at $64.20 on Thursday. Haemonetics Co. has a fifty-two week low of $55.30 and a fifty-two week high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The stock's fifty day moving average is $62.64 and its two-hundred day moving average is $71.49. The firm has a market capitalization of $3.23 billion, a P/E ratio of 25.28, a PEG ratio of 1.11 and a beta of 0.32.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Research analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on HAE shares. JMP Securities lowered their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a report on Friday, February 7th. StockNews.com upgraded Haemonetics from a "hold" rating to a "buy" rating in a research note on Monday. Barrington Research reduced their price target on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Raymond James restated a "strong-buy" rating and issued a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Finally, Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and cut their target price for the company from $95.00 to $68.00 in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.